Literature DB >> 12720129

Abnormal expression of hyaluronan synthases in patients with Waldenstrom's macroglobulimenia.

Sophia Adamia1, Mary Crainie, Jitra Kriangkum, Michael J Mant, Andrew R Belch, Linda M Pilarski.   

Abstract

Little is known about the biology or spread of Waldenstrom's macroglobulinemia (WM), a lymphoplasmo-proliferative disorder. Hyaluronan synthases (HASs), plasma membrane proteins, synthesize the extracellular matrix molecule hyaluronan (HA), which plays a role in malignant cell migration and the spread of many cancers. Three isoenzymes of HAS-HAS1, HAS2, and HAS3-are detected in humans. Aberrant expression of the HASs is coupled with different abnormalities. We have analyzed the expression pattern of HASs in WM patients. HAS3 was expressed in all patients and healthy donors tested, whereas the expression of HAS1 and HAS2 varied among the WM patients. Additionally, in WM patients, we have detected novel variants of HAS1, one of which was also detected in multiple myeloma (MM) patients. We speculate that HAS1 variants synthesize the intracellular HA ligand for RHAMM (a receptor for HA). RHAMM contributes to genetic instability in MM; therefore, we speculate that it may also contribute to genetic instability in WM. Furthermore, we suggest that overexpression of HAS1 and its variants in combination with HAS3 may form an HA matrix around WM cells, thus preventing their elimination by the immune system, and it promotes their migration and may facilitate the spread of disease. Copyright 2003 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12720129     DOI: 10.1053/sonc.2003.50042

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  7 in total

Review 1.  Dissecting the role of hyaluronan synthases in the tumor microenvironment.

Authors:  Alberto Passi; Davide Vigetti; Simone Buraschi; Renato V Iozzo
Journal:  FEBS J       Date:  2019-04-22       Impact factor: 5.542

2.  Intronic splicing of hyaluronan synthase 1 (HAS1): a biologically relevant indicator of poor outcome in multiple myeloma.

Authors:  Sophia Adamia; Tony Reiman; Mary Crainie; Michael J Mant; Andrew R Belch; Linda M Pilarski
Journal:  Blood       Date:  2005-02-24       Impact factor: 22.113

Review 3.  Biology of hyaluronan: Insights from genetic disorders of hyaluronan metabolism.

Authors:  Barbara Triggs-Raine; Marvin R Natowicz
Journal:  World J Biol Chem       Date:  2015-08-26

4.  Aberrant splice variants of HAS1 (Hyaluronan Synthase 1) multimerize with and modulate normally spliced HAS1 protein: a potential mechanism promoting human cancer.

Authors:  Anirban Ghosh; Hemalatha Kuppusamy; Linda M Pilarski
Journal:  J Biol Chem       Date:  2009-05-18       Impact factor: 5.157

Review 5.  Hyaluronan synthase 1: a mysterious enzyme with unexpected functions.

Authors:  Hanna Siiskonen; Sanna Oikari; Sanna Pasonen-Seppänen; Kirsi Rilla
Journal:  Front Immunol       Date:  2015-02-05       Impact factor: 7.561

6.  Human hyaluronic acid synthase-1 promotes malignant transformation via epithelial-to-mesenchymal transition, micronucleation and centrosome abnormalities.

Authors:  Nguyet Nguyen; Awanit Kumar; Simi Chacko; Rodney J Ouellette; Anirban Ghosh
Journal:  Cell Commun Signal       Date:  2017-11-14       Impact factor: 5.712

7.  Alteration of introns in a hyaluronan synthase 1 (HAS1) minigene convert Pre-mRNA [corrected] splicing to the aberrant pattern in multiple myeloma (MM): MM patients harbor similar changes.

Authors:  Jitra Kriangkum; Amanda Warkentin; Amanda Warkinton; Andrew R Belch; Linda M Pilarski
Journal:  PLoS One       Date:  2013-01-03       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.